No price history available.
Key financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | KRWm | 559,103 | 594,193 | 661,647 | 730,994 | 812,166 | 926,884 | N/A | N/A |
| Operating profit | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | KRWm | 55,925 | 50,345 | 52,896 | 47,175 | 61,219 | 66,020 | N/A | N/A |
| EPS reported | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
DongKook Pharmaceutical Co., Ltd., established in Seoul, South Korea in 1968, operates as a pharmaceutical company with a broad presence both domestically and globally. Formerly known as UEC & Co., Ltd. until its rebranding in March 1982, the firm manufactures and distributes a diverse array of healthcare products. Its offerings include essential active pharmaceutical ingredients like propofol, streptokinase, and teicoplanin. The company also produces a wide range of finished drug forms such as disposable syringes, tablets, capsules, and topical ointments, in addition to various injectable solutions including small and large volume parenterals, and lyophilized medications. Specific branded injections like Teicon, Durakinase, and Lorelin Depot are also part of its portfolio. Furthermore, DongKook develops and supplies natural product derivatives, featuring black cohosh and magnolia extracts (marketed as ETIZM and TECA), alongside traditional herbal remedies. Its extensive inventory also encompasses general and prescription-based drugs, medical equipment, ethical and beauty products, and specific quasi-drugs, such as the lipossol hydrocare bandage. The company's market reach extends to roughly 40 nations, with substantial exports to regions including Japan, Europe, Central and South America, and India.
Similar companies
- Nanjing Hicin Pharmaceutical Co., Ltd.
- PT Industri Jamu dan Farmasi Sido Muncul Tbk
- TTY Biopharm Company Limited
- ZhuZhou QianJin Pharmaceutical Co.,Ltd
- Zhejiang Yatai Pharmaceutical Co., Ltd.
- Lionco Pharmaceutical Group Co.,Ltd.
- Henan Taloph Pharmaceutical Stock Co.,Ltd
- Hunan Fangsheng Pharmaceutical Co., Ltd.
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
DongKook Pharmaceutical Co., Ltd. (086450.KQ)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
DongKook Pharmaceutical Co., Ltd., established in Seoul, South Korea in 1968, operates as a pharmaceutical company with a broad presence both domestically and globally. Formerly known as UEC & Co., Ltd. until its rebranding in March 1982, the firm manufactures and distributes a diverse array of healthcare products. Its offerings include essential active pharmaceutical ingredients like propofol, streptokinase, and teicoplanin. The company also produces a wide range of finished drug forms such as disposable syringes, tablets, capsules, and topical ointments, in addition to various injectable solutions including small and large volume parenterals, and lyophilized medications. Specific branded injections like Teicon, Durakinase, and Lorelin Depot are also part of its portfolio. Furthermore, DongKook develops and supplies natural product derivatives, featuring black cohosh and magnolia extracts (marketed as ETIZM and TECA), alongside traditional herbal remedies. Its extensive inventory also encompasses general and prescription-based drugs, medical equipment, ethical and beauty products, and specific quasi-drugs, such as the lipossol hydrocare bandage. The company's market reach extends to roughly 40 nations, with substantial exports to regions including Japan, Europe, Central and South America, and India.
- Nanjing Hicin Pharmaceutical Co., Ltd.
- PT Industri Jamu dan Farmasi Sido Muncul Tbk
- TTY Biopharm Company Limited
- ZhuZhou QianJin Pharmaceutical Co.,Ltd
- Zhejiang Yatai Pharmaceutical Co., Ltd.
- Lionco Pharmaceutical Group Co.,Ltd.
- Henan Taloph Pharmaceutical Stock Co.,Ltd
- Hunan Fangsheng Pharmaceutical Co., Ltd.
